Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell Lymphoma Clinical Trial

Official title:
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma: an Open Label, Single Arm, Phase II Study

Status Recruiting

Clinical Trial Summary

The purpose of this open label,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide combination with lenalidomide for relapsed or refractory peripheral T-cell lymphoma.

Clinical Trial Description

Histone deacetylase(HDAC) inhibitor has been used in relapsed or refractory peripheral T-cell lymphoma.There are no international studies of Chidamide combination with lenalidomide for relapsed or refractory peripheral T-cell lymphoma. Therefore, this study intends to select the oral HDAC inhibitor Chidamide combined with lenalidomide for relapsed or refractory peripheral T-cell lymphoma, and explore its efficacy and safety. ;

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Relapsed or Refractory Peripheral T-cell Lymphoma

Clinical Trial Details

NCT number	NCT04329130
Study type	Interventional
Source	Sun Yat-sen University
Contact	Qingqing Cai, MD
Phone	0086-20-87342823
Email	caiqq@sysucc.org.cn
Status	Recruiting
Phase	Phase 2
Start date	March 27, 2020
Completion date	March 26, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03356678` - Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma	N/A
Completed	`NCT02464228` - Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.	Phase 2
Recruiting	`NCT04108325` - A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma	Phase 1
Recruiting	`NCT05833724` - Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)	Phase 2